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Peripheral T-cell lymphomas (PTCLs) receiving conventional treatment have a poor clinical 
outcome. We conducted a phase II study to evaluate the feasibility and efficacy of chemo-
immunotherapy in young ( 60 years old, Clin A study) and elderly (>60 and 75 years old, 
Clin B study) patients with newly diagnosed PTCL. Clin A patients (n=61) received two courses of 
CHOP (cyclophosphamide, adriamycin, vincristine, prednisone)-21 with alemtuzumab (AL, 30 mg) 
followed by two courses of high-dose chemotherapy. On the basis of donor availability, patients in 
response received allogeneic (allo) or autologous (auto) stem cell transplantation (SCT). Clin B 
patients (n=25) received six courses of CHOP-21 and AL (10 mg). Clin A responding patients were 
38 of 61 (62%) and received alloSCT (n=23) or autoSCT (n=14); one complete remission (CR) 
patient was not transplanted. At a median follow-up of 40 months, the 4-year overall survival (OS), 
progression-free survival (PFS) and disease-free survival (DFS) rates were 49, 44 and 65%, 
respectively. In Clin B study, the response rate was 72%. At a median follow-up of 48 months, the 
4-year OS, PFS and DFS rates were 31, 26 and 44%, respectively. In conclusion, front-line alloSCT 
or autoSCT is effective in prolonging DFS in young patients; AL in elderly improved response with 
no survival benefit. 
  
Introduction 
Peripheral T-cell lymphomas (PTCLs) are a rare and heterogeneous group of lymphoid 
malignancies usually presenting with advanced stage disease. CHOP (cyclophosphamide, 
adriamycin, vincristine, prednisone) or CHOP-like regimens are still considered as the standard 
treatment for PTCLs
1
 and are associated with a dismal outcome of a 5-year overall survival (OS) in 
~25–30%. Anaplastic large cell lymphoma (ALCL), expressing the anaplastic lymphoma kinase 
(ALK), represents an exception with a more favorable outcome.
2
 
In recent years, different trials have focused on modifications of conventional chemotherapy. The 
German High-Grade Non-Hodgkin Lymphoma study group showed that the addition of etoposide 
to CHOP (CHOEP) improved event-free survival (EFS) in a selected cohort of young patients with 
normal lactate dehydrogenase values, essentially including ALK-positive ALCL (3-year EFS of 
91%),
3
 but failed to improve the outcome of elderly patients. Due to a consistent expression of 
CD52 antigen in PTCL-not otherwise specified (PTCL-NOS) and angioimmunoblastic lymphomas 
(AILT),
4, 5
 the anti-CD52 monoclonal antibody (alemtuzumab, AL) was used to explore the role of 
chemo-immunotherapy in PTCLs. Phase II trials combining CHOP and AL reported promising 




Therapy intensification with up-front autologous stem cell transplantation (autoSCT) was explored 
in phase II studies and resulted in a 3-year EFS ranging from 30 to 50%.
9, 10, 11, 12
 Recently, the 
Nordic Lymphoma group reported the results of up-front autoSCT following six courses of 
CHOEP-14. With a median follow-up of 60 months, the estimated 5-year OS and progression-free 
survival (PFS) were 51 and 44%, respectively.
13
 With regard to salvage therapy, allogeneic SCT 




Bearing in mind all these findings, we designed a phase II trial enrolling young ( 60 years old, 
Clin A study) and elderly (>60 and 75 years old, Clin B study) patients. Patients in Clin A 
study received an induction phase consisting of CHOP-AL and high-dose chemotherapy followed 
by consolidation with alloSCT or autoSCT, depending on donor availability. Patients in Clin B 
study received a reduced dose of AL in combination with CHOP to increase the response rate while 
limiting toxicity. 
  
Materials and methods 
Patient characteristics 
From November 2006 to November 2010, 92 patients were enrolled by 18 Italian Centers. 
Eligibility criteria were the following: (1) histologically proven diagnosis of PTCL-NOS, ALK-
negative ALCL, AILT or enteropathy-associated T-cell lymphoma (EATL); (2) advanced stage 
disease (stage II–IV) or stage I disease with an International Prognostic Index (IPI) score of 2; 
(3) preserved organ function; (4) the absence of prior chemo-radiotherapy. Diagnosis was 
performed according to the WHO (World Health Organization) classification and verified by a 
central pathology review.
17, 18
 In our trial, the expression of CD52 was not assessed on paraffin 
blocks. 
Patient characteristics are reported in Table 1. Clin A enrolled 64 patients, although 3 were 
excluded: 2 after pathological review (T-lymphoblastic lymphoma (n=1); ALK-positive ALCL 
(n=1)) and 1 for previous radiotherapy. In all, 61 patients were analyzed: 33 PTCL-NOS, 12 ALK-
negative ALCL, 14 AILT and 2 EATL. The median age was 48 years old (range: 24–60 years old). 
Clin B enrolled 28 patients before it was stopped for toxicity by the Data and Safety Monitoring 
Board. Three patients were excluded from the analysis: two patients died before starting the 
treatment protocol (myocardial ischemia (n=1), progressive disease (n=1)) and one who was 
diagnosed as T-lymphoblastic lymphoma. Analysis was performed on 25 cases: 9 PTCL-NOS, 7 










Table 1 - Patient characteristics at diagnosis. 
 
 
The study was approved by the Ethical Committees of participating centers and received a grant for 
Good Clinical Practice conduction from the Italian Ministry of Health. Written informed consent 
was obtained from all patients. The study was registered in the University Hospital Medical 
Information Network Clinical Trials Registry (EudraCT Number 2006-004234-33). 
Treatment plan 
Clin A consisted of an induction and a transplantation phase (Figure 1). Induction phase: consisted 
of (1) CHOP (doxorubicin 50 mg/m2, vincristine 1.4 mg/m2 (maximum total dose 2.0 mg), 
cyclophosphamide 750 mg/m2 intravenously on day 1, prednisone 100 mg orally on days 1 through 
5) and intravenous AL (Mabcampath, Genzyme Europe, Netherlands) administered according to the 
following schedule: 3 mg, 10 mg, 20 mg, days −2, −1, 0 (before the first CHOP cycle), 30 mg on 
day 0 from the second CHOP cycle; (2) two courses of HyperCHidam: high-dose methotrexate 
given as a continuous infusion (1.6 g/m2) on day 1; cyclophosphamide 300 mg/m2 and high-dose 
cytarabine 2 g/m2 every 12 h for 3 days. Granulocyte-colony stimulating factor 5 mcg/kg per day 
was given from day +5.
19
 Leukaphereses were planned after the first or second (in case of marrow 
involvement) HyperCHidam. Transplantation phase: Patients achieving a partial (PR) or complete 
remission (CR) with an human leukocyte antigen-identical sibling (or 1 antigen mismatched) or 
with a matched unrelated donor received alloSCT. The conditioning regimen included thiotepa, 
fludarabine and cyclophosphamide, as previously described.
20
 Anti-thymocyte globulin was 
administered for mismatched siblings and unrelated donors (thymoglobulin 3.5 mg/kg daily on days 
−4 and −3). This regimen was followed by the infusion of alloSCT (5–8 × 106/kg CD34+) (on day 
0). The donors included 13 matched siblings and 10 matched unrelated donors. 
Figure 1. Flow chart of the Clin A and Clin B studies. 
 
For patients in clinical response without a suitable donor, autoSCT was performed following a 
regimen consisting of carmustine, etoposide, cytarabine and melphalan (BEAM). The infusion of 
autologous peripheral blood progenitor cells was performed on day 0 (>4 × 10
6
 CD34+/kg). 
Clin B consisted of a combination of AL (10 mg) and CHOP for six courses (CHOP-21) (Figure 1). 
Additional information is provided in the Supplementary Information. 
Response assessment and toxicity criteria 
The response to therapy was defined according to Cheson et al.
21
 In Clin A, treatment response was 
evaluated after the induction phase, 1 month after transplant and then every 3 months for the first 2 
years and every 6 months thereafter. In Clin B, response was evaluated after 3 and 6 cycles, every 3 
months for the first 2 years and every 6 months thereafter. Toxicity assessment was performed 
according to NCI Criteria for adverse events, version 3.0, cancer therapy evaluation program, 
CTCAE (http://ctep.cancer.gov). 
Study design and statistical methods 
The study included two prospective phase II trials: Clin A designed for young patients ( 18 and 
60 years old) and Clin B for the elderly (>60 and 75 years old). Both Clin A and Clin B 
studies were planned according to the Simon optimal two-stage study design.
22
 Efficacy analyses 
were performed on all accrued patients, by the intention-to-treat principle. The primary end point 
was treatment efficacy defined as CR maintained for at least 6 months. Secondary end points were 
disease-free survival (DFS, estimated on two subsets: (1) all CR patients; (2) only CRs maintained 
for at least 6 months), PFS, OS, non-relapse mortality (NRM) incidence and relapse incidence. The 
Kaplan–Meier method was used to estimate the DFS, PFS and OS curves, which were compared 
using the log-rank test. The crude cumulative incidence curves of NRM were estimated considering 
relapse as a competing event, and comparisons between curves were carried out using the Gray 
test.
23
 Univariate analyses (Kaplan-Meier and crude cumulative incidence curves) were performed 
according to the patient’s age (<48 years (median value), 48 years), sex, IPI, prognostic index 
for PTCL-NOS (PIT), histological subtype, the presence or absence of extranodal disease 
(liver/gastrointestinal involvement) and transplant type (auto, allo). Multivariable analyses of PFS 
and OS were performed using Cox regression models,
24
 which included clinical response modeled 
as a binary time-dependent variable, together with patient’s age (as continuous variable), IPI and 
extranodal disease as adjustment factors. In Clin A only, alternative models included transplantation 
as a binary time-dependent variable instead of clinical response. Additional information is provided 
in the Supplementary Information. 
  
Results 
Response to treatment: Clin A study 
CHOP-AL therapy was started in 61 patients, but 5 progressed after the first (n=3) or the second 
cycle (n=2) and received a salvage therapy; 56 patients received the first HyperCHidam course, 
whereas the second was administered to 44 patients. The median time between cycles of CHOP-AL 
was 23 days (range, 19–60). The median time between cycles of HyperCHidam was 39 days (range, 
19–87). 
The reasons for not receiving the second HyperCHidam cycle were the following: PD (n=6), toxic 
deaths (n=3), grade 3–4 adverse events during the first cycle (n=3). These last three patients 
proceeded directly to the transplantation phase. Overall, at the end of the induction phase, 40 of 61 
patients responded (65%), and among them there were 33 CRs (54%) and 7 PRs (11%). In all, 37 of 
40 patients underwent alloSCT (n=23) or autoSCT (n=14); 2 patients in the CR group died of 
infectious complications before transplantation, and 1 CR patient did not receive autoSCT due to a 
prior systemic herpes-zoster infection complicated by prolonged neutropenia. Thus, 24 of 61 
patients (39%) enrolled in this intensified program did not undergo transplantation because of three 
reasons: (1) progressive disease (n=18); (2) toxic death (n=5); (3) physician decision (n=1 in CR). 
Before alloSCT, 20 patients (87%) were in CR and 3 (13%) in PR. At a median follow-up of 44 
months, 16 patients were still in CR, whereas 4 have relapsed (17%) and died of PD. The last three 
patients, who were in CR before alloSCT, died of NRM after allograft (pneumonia (n=1), 
encephalitis (n=1) and acute graft-vs-host disease (GVHD) (n=1)). 
Twenty-three patients received alloSCT (n=13 from matched sibling donors and n=10 from 
matched unrelated donors). Only 22 patients were evaluable for acute GVHD (1 patient died early 
for NRM). Acute GVHD of grade 2–4 occurred in 9 of 22 patients (40%) (only 2 experienced 
GVHD of grade III and IV). Only 22 patients were evaluable for chronic GVHD (2 were not 
evaluable for early death); chronic GVHD occurred in 11 of 21 patients (52%) (n=9 limited and n=2 
extensive). 
Before autoSCT, 10 patients (71%) were in CR and 4 in PR (29%). At a median follow-up of 32 
months, all but 1 patient were alive in CR. Four patients relapsed, and three of them achieved long-
term remission with salvage alloSCT. 
Response to treatment: Clin B study 
Overall response rate was 72%, with 18 of 25 patients responding (15 CR and 3 PR) to the complete 
treatment of 6 CHOP-AL courses. There were 6 early progressions during treatment and one early 
toxic death. In the contest of the 18 responding patients, 7 maintained their response until the last 
follow-up, and 2 died of toxicity. Eight patients were alive at last follow-up. 
Survival and prognostic factors 
In the Clin A study, the 4-year OS, PFS and DFS rates were 49% (95% confidence interval (CI), 
37–63%), 44% (95% CI, 33–58%) and 65% (95% CI, 51–83%), respectively (Figure 2). The DFS 
for patients maintaining the response for at least 6 months was 78% (95% CI, 65–95%). 
Figure 2.  
Clin A study: Kaplan–Meier survival curves: (a) DFS; (b) DFS of the Clin A trial for patients 
who maintained the CR for at least 6 months; (c) PFS; and (d) OS. 
 
  
Univariate analyses were performed, regarding the impact of age, sex, performance status, IPI, PIT, 
histological subtype, extranodal disease and transplant type on outcome. On univariate analysis, 
gastrointestinal and liver involvement was associated with a shorter PFS (21 vs 51%, P=0.035), and 
there was a trend for shorter OS (26 vs 55%, P=0.061). In our population, the IPI and the PIT did 
not achieve statistical significance for PFS and OS (IPI: 2 vs <2; PFS: 39 vs 58% (P=0.22); 
OS: 41 vs 62% (P=0.16)). We did not observe a significant difference in the outcome between the 
different histotypes. At 40 months of median follow-up, PFS and OS were as follows in different 
subtypes: 47 and 50% for PTCL-NOS; 36 and 54% for ALK negative, and 50 and 50% for AILD 
(Figure 1; Supplementary Information). 
Survival outcomes after SCT were not significantly different, with a 4-year OS of 92% for autoSCT 
and 69% for alloSCT (P=0.10). Similarly, 4-year PFS was 70 and 69% for those receiving autoSCT 
or alloSCT (P=0.92), respectively (Figure 2; Supplementary Information). However, we must note 
that our study was not designed and powered to evaluate the differences between transplant types. 
On multivariable analysis (Table 2, Model 1), the achievement of CR maintained for at least 6 
months had a dominant effect on PFS and OS, regardless of the patient’s age, IPI or extranodal 
involvement. Patients who received a transplant had an advantage in OS (hazard ratio (HR)=0.04; 
95% CI, 0.01–0.37, P=0.004 for autoSCT; HR=0.22; 95% CI, 0.07–0.67, P=0.008 for alloSCT; 
Table 2, Model 2). 
Table 2 - Clin A: multivariable Cox model analyses of PFS and OS with clinical response (Model 1) or transplant 
(Model 2) as time-dependent variables. Clin B: multivariable Cox model analyses of PFS and OS with clinical 
response as the time-dependent variable. 
 
 
In Clin A, 8 of 61 patients died of treatment-related causes with a cumulative incidence of NRM of 
13%; 5 died after HyperCHidam of infections (n=4) or multiorgan failure (n=1), whereas 3 died 
after alloSCT (n=1 encephalitis, n=1 GVHD, n=1 pneumonia). 
In the Clin B study, the estimated 4-year OS, PFS and DFS rates were 31% (95% CI, 17–56%), 
26% (95% CI, 13–52%) and 44% (95% CI, 24–80%), respectively (median follow-up of 48 
months) (Figure 3). The DFS for the 13 patients maintaining the response for 6 months was 51.3% 
(95% CI, 29–89%). On univariate analysis, gastrointestinal and liver involvement was associated 
with a trend toward reduced PFS (4-year estimates: 14 vs 31%, P=0.075) and reduced OS (14 vs 
38%, P=0.034). On multivariable analysis (Table 2), the achievement of a CR maintained for at 
least 6 months was the factor associated with the longest PFS (HR=0.20; 95% CI, 0.04–0.91; 
P=0.038) and OS (HR=0.05; 95% CI, 0.01–0.48; P=0.009). 
Figure 3.  
Clin B study: Kaplan–Meier survival curves: (a) DFS; (b) DFS of the Clin B trial for patients 
who maintained the CR for at least 6 months; (c) PFS; (d) OS. 
 
In Clin B, 3 of 25 patients died of infectious complications (pneumonia (n=2) and cytomegalovirus 
(CMV) encephalitis (n=1)), resulting in a cumulative incidence of NRM of 12%. Considering the 
slow accrual and the high NRM with conventional dose chemotherapy, the Data and Safety 
Monitoring Board stopped the Clin B study. 
Adverse events 
Table 3 shows all grade 3–4 adverse events that occurred during the induction phase. Following 
CHOP-AL, we observed mainly hematological toxicity. CMV reactivation was described in 17 of 
119 cycles (14%). Infectious complications were very common after the first (17 of 56) or the 
second (15 of 44) cycle of HyperCHidam. CMV reactivation was reported in seven and five patients 
receiving the first or second cycle of HyperCHidam, respectively. 
Table 3 - Incidence and maximum severity of adverse events (grade 3–4). 
 
In Clin B, severe infectious complications occurred in 10 of 128 cycles (8%). CMV reactivation 




The background of the present study relies on previous studies accomplished by our group showing: 
(1) an improved response rate induced by the combination of CHOP and AL in PTCLs at 
diagnosis;
6
 (2) the feasibility of high-dose chemotherapy and up-front autoSCT;
9
 and (3) the role of 
alloSCT as an effective salvage treatment.
14, 15
 Thus, we designed a study in which chemo-
immunotherapy was used both in young and in elderly patients with the aim of improving the 
overall response rate and thus the survival outcome. According to the donor availability, young 
patients received either alloSCT or autoSCT as a consolidation treatment. This study was the first 
that tested the feasibility and efficacy of front-line alloSCT in PTCL. 
In PTCL, the treatment with an anthracycline-based therapy is associated with clinical remission in 
more than half of the treated patients; however, the prognosis remains poor with a 5-year survival of 
30–35%.25 Modifications to the CHOP-based chemotherapy include the addition of etoposide, 
bortezomib or immunotherapy. In a large retrospective study conducted by Schmitz et al.,
3
 CHOP 
plus etoposide improved EFS but not OS in young patients with normal lactate dehydrogenase 
levels. However, in this analysis most patients were affected by ALCL and had a low IPI. A recent 
phase II study evaluated the combination of bortezomib and CHOP; despite the high response rate, 
the 3-year PFS and OS were not better than historical controls using CHOP alone.
26
 AL was given 
in combination with CHOP at various schedules and doses; the achievement of CR varied from 65 
to 70%, although with a quite limited advantage in terms of EFS.
6, 7, 8
 
Despite the absence of phase III trials, the consolidation of response with autoSCT is commonly 
employed in the clinical practice and the evidence is mostly derived from phase II studies. The most 
recent prospective trials of up-front autoSCT reported a favorable outcome with 3-year PFS and OS 
ranging from 36 to 48% and from 48 to 56%, respectively.
12, 13
 Reimer et al. found a significant 
correlation between PIT and OS. D’Amore et al. identified ALK-negative histology as a favorable 
prognostic factor whereas bone marrow involvement, performance status and age were associated 
with poor outcomes. 
Given the concern about NRM, first-line consolidation with alloSCT has been explored only in very 
few retrospective studies. Kanakry et al.
27
 reviewed the outcomes of 44 patients allografted from 
haplo donors (n=22) or human leukocyte antigen-matched related donors (n=20). These authors 
observed a trend toward better PFS for alloSCT in first remission vs beyond first remission (2-year 
PFS: 53 vs 29%). Recently, Smith et al.
28
 retrospectively analyzed the outcome of patients 
undergoing autoSCT (n=115) or alloSCT (n=126). This large registry study has some caveats, 
among which there is the inclusion of a limited number of patients transplanted at the first CR, and 
the enrollment of a large number of patients with ALCL histology without additional information 
regarding the ALK status. Despite these limitations, a number of observations emerged: (1) patients 
autografted at the first CR had a 3-year PFS of 58%; (2) one-third of patients allografted remained 
disease free despite being transplanted with relapsed disease; and (3) the higher incidence of disease 
relapse in the autoSCT group was balanced out by a higher NRM in the alloSCT group. 
In Clin A, at the end of the induction phase the CR rate was 54%. The consolidation with alloSCT 
or autoSCT was effective, since the DFS at 4 years was 79% in the patients maintaining the CR for 
at least 6 months. In agreement with our previous study of up-front autoSCT,
9
 the only factor 
influencing the outcome was the achievement of a stable CR, regardless of IPI or PIT. With a 
median follow-up of 40 months, PFS and OS (44 and 49%, respectively) are in line with, but not 
higher than the best published data.
12, 13
 Although a formal comparison between the two 
transplantation strategies is not possible, no significant difference was found. 
Despite the use of intensified chemo-immunotherapy, in the present trial 18 of 61 (30%) young 
patients did not undergo transplantation for progressive disease. A similar percentage is also 
described in other studies. This is rather disappointing and represents the main unmet clinical need 
in PTCLs. For future improvement, we may envisage three main areas: (1) prognostic factors and 
biomarkers, (2) molecular profiling for better diagnostic accuracy and (3) novel drugs. 
Apart from patient-specific clinical factors (IPI and PIT) and tumor-specific characteristics 
(histotype, ki-67 expression 80%, expression of cytotoxic molecules), very few prognostic 
factors are currently available to identify poor prognosis patients early during their clinical course. 
A potential novel biomarker is based on the inactivating mutations of the Ten-Eleven translocation 
2 that have been associated with a shorter PFS and OS.
29
 Molecular profiling could be helpful, but 
the large-scale applicability remains a matter of debate.
30
 There are novel active drugs: 
bendamustine, pralatrexate, romidepsin and brentuximab-vedotin (only for CD30-positive T 
lymphomas) have been recently investigated in relapsed patients, with promising response rates.
31, 
32, 33, 34
 Consequently, a possible aim of future studies will be the front-line introduction of novel 
agents in combination with chemotherapy and/or SCT. 
Patients enrolled in the Clin B study were at high risk, due to an IPI of 2 and a PIT of 2–4. Our 
trial evaluated CHOP-21 and reduced AL dose for the first time in elderly patients, and 
demonstrated a clinically relevant toxicity with three treatment-related deaths. Despite an 
encouraging overall response rate (72%), the majority of patients relapsed, resulting in 
disappointing survival outcomes. Due to the high-relapse rate and significant toxicity, this study 
was closed prematurely by the Data and Safety Monitoring Board. Few data are available for the 
treatment of elderly patients. The study by Schmitz et al.
3
 reported the treatment of 90 patients over 
60 years of age with CHOP or CHOEP at 2- or 3-week intervals. The outcome was not improved by 
dose-dense chemotherapy or by the addition of etoposide. 
The goal of our intensified chemo-immunotherapy was to improve the response rate. This strategy 
was associated with some toxicity (13 and 12% for NRM in Clin A and Clin B studies, 
respectively). This finding can be explained by several factors: (1) patients affected by PTCLs have 
a profound disease-related immunodeficiency; (2) the administration of AL before the intensive 
chemotherapy most likely increased the infectious complications in the Clin A study (in fact, two 
doses of AL produced a profound decline in circulating T cells before the administration of high-
dose chemotherapy); (3) the HyperCHidam regimen has been evaluated for the first time by 
Todeschini et al.
19
 in 28 patients affected by relapsed and refractory Hodgkin and non-Hodgkin 
lymphomas. In that group of patients, heavily pretreated, the authors described three toxic deaths 
and a high incidence of infectious complications. In our cohort of patients, pretreated only with two 
cycles of CHOP-AL, we observed five deaths after HyperCHidam. Therefore, we think that this 
combination of drugs and not only AL influenced the NRM; (4) even when used at a reduced dose, 
AL still causes serious immunodeficiency in elderly patients. The higher NRM reported in our 
study can not only be explained by the higher median age of the patients but also by the advanced 
disease status (100% had IPI score 2) and by the poor performance status (32% had an eastern 
cooperative oncology group of 2 or 3); (5) although low, the alloSCT NRM was higher than that of 
conventional therapy or autoSCT, and this had an influence on OS. 
In conclusion, our trial demonstrated several novel and important findings. First, AL cannot be 
safely associated with high-dose chemotherapy. AlloSCT or autoSCT can be used as a front-line 
treatment to consolidate the response and prolong DFS, but allografting is not yet indicated outside 
a clinical trial. In addition, low-dose AL in the elderly is still associated with relevant toxicity 
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